



KRKA GROUP

Q1 2026 Business Performance Presentation

David Bratož,
Member of The Management Board

14 May 2026

Krka Group Business Performance

Q1 2026 unaudited financial statements highlights

- ✓ **Record sales: €566m; +8% yoy**
- ✓ **EBITDA margin: 31%; EBITDA of €176m +20% yoy**
- ✓ **EBIT margin: 26.8%; EBIT of €152m +24% yoy**
- ✓ **Net profit margin: 21.4%**
- ✓ **Net profit of €121m -21% yoy; due to less favorable FX impact**
- ✓ Sales increased in all regions, except West Europe, and all products & service groups except OTC.
- ✓ Rx remains the most important product group (84% of sales) contributing the most to increased sales figures
- ✓ 4 new MA and CAPEX of €23m
- ✓ RUB volatility affecting operating and net financial result: -€3.3m (vs Q1 2025 +€57m).




Worldwide, Krka's medicines are used by more than **100 million people**



19 billion finished products are manufactured annually across various therapeutic groups

5-year average Q1 sales of products and services growth: 7.4%




Krka Group Sales by Regions


Present in more than 70 countries worldwide

Q1 2026: EUR 564 million of goods and services

(+8% yoy; + EUR 43 million)




Top 6 countries by sales



Absolute and relative changes compared to the same period last year

Broad Product Portfolio

Rx remains the most important product group, with EUR +42.5 million sales increase



MORE THAN 1,000 PRODUCTS AND MORE THAN 250 ACTIVE INGREDIENTS

Absolute and relative changes compared to the same period last year




Research and Development

Innovative branded generic producer, with own R&D

Competitive advantage – Overcoming regulatory challenges by leveraging established expertise to introduce innovative products

4 New products:

- **Mempoglyn* (empagliflozin, metformin)** – A new single-pill combination film-coated tablet combining two active substances with complementary mechanisms of action for a modern, comprehensive approach to the treatment of type 2 diabetes.
- **Lymereo* (linagliptin, metformin)** – A new fixed-dose combination film-coated tablet enabling effective treatment of type 2 diabetes and therapy adjustment according to patients' needs.
- **Dulsevia*/Loxentia (duloxetine)** – A reformulated established medicine in gastro-resistant hard capsules for the treatment of central nervous system disorders, such as depression and anxiety.
- **Robexera/Rogiola (robenacoxib)** – A new veterinary product in chewable tablets for cats, expanding Krka's range of analgesics for companion animals.



More than **800** experts work in R&D



More than **170** products in the pipeline



For R&D we allocate **10%** of revenue annually

Krka's Innovative Medicines

Innovative branded generic producer, with own R&D

STATE-OF-THE-ART EQUIPMENT

Delivering the most demanding projects in terms of techniques and technologies

ADVANCED PHARMACEUTICAL FORMULATIONS

Great possibility of differentiation to other generics and originator

UNIQUE STRENGTHS

Tailoring the treatment to patients needs

UNIQUE SINGLE PILL COMBINATIONS

Synergistic action & improved adherence for patients

>150
SPCs

1000 products based on **250+ active ingredients** (Rx, OTC & VET products)



1st generic manufacturer in the global pharma market to offer the **triple SPC** of **perindopril, indapamide and amlodipine**

PATENT-PROTECTED INNOVATIONS

250

Continuous investments


Strengthening our vertical integration



Investments are primarily directed toward increasing and technologically upgrading production capacities, as well as capacities for development and quality management

In 2025 we finalised the following investments:

- At Notol, our production plant in Novo mesto, Slovenia, we replaced 16 packaging lines, installed robotic cells, and upgraded washing and granulation systems.
- We finished the construction of the technologically advanced waste-water treatment plant in Krško, Slovenia.
- Ljutomer plant, Slovenia – finished the capacity expansion. Construction of an automated high-bay warehouse and an expansion of the plant are under way.



Investments in Progress

NOTOL and NOTOL 2 Slovenia, Novo mesto

- Ensuring reliable operations over the next 20 years, alongside an extension designed to increase production capacity. The installation of additional equipment at Notol 2, another production plant in Novo mesto, Slovenia, will further boost production capacities.

BRŠLJIN Slovenia

- Increasing packaging capacities for tablets and spot-on products for veterinary use. Main goal is to increase production capacities for veterinary products and their packaging. The construction of a multi-storey building is in progress at the same site.

Jastrebarsko, Croatia

- Increasing production capacity at the production and distribution centre.

Ningbo Krka Menovo Pharma Co, China

- We set up product manufacturing to support animal health product programme. We installed and qualified a filling-and-packaging line.

KRKA PHARMA PRIVATE LIMITED Hyderabad, India


- Construction of research and production facilities for oncology products and solid dosage forms is underway



Financial results


Income statement

EUR thousand	Q1 2026	(%)	Q1 2025	(%)	YoY
Revenue	565,774	100	522,114	100	8%
Costs of goods sold	223,773	40	217,697	42	3%
Gross profit	342,001	60	304,417	58	12%
Other operating income	1,347	0	1,427	0	-6%
Selling and distribution expenses	105,924	19	100,803	19	5%
R&D expenses	51,371	9	49,519	9	4%
General and administrative expenses	34,452	6	32,832	6	5%
Operating profit	151,601	27	122,690	23	24%
Net financial result	-3,329		56,824		
Profit before tax	148,272	26	179,514	34	-17%
Income tax	27,322		27,030		1%
Net profit	120,947	21	152,484	29	-21%
Basic earnings per share (EPS) in €	3.69		4.97		-26%



FX Impact

Lower positive FX differences contribution to NFI in Q1 2026




- The impact of currencies on the Group's net financial result was **negative in the first quarter of 2026**.
- The value of the **RUB declined by 1.4% in Q1 2026**, while its average value was 7.1% higher than in the same period last year.
- The value of the **USD increased by 2.2% in Q1 2026**, while its average value was 10.1% lower than in the same period last year.
- Other currencies were mostly stable in the first three months of 2026.
- We generated a **net financial result of EUR -3.3 million**, which is EUR 60.2 million less than in the same period last year.
- The year-on-year difference was due to the high positive base in Q1 2025, which resulted from the strengthening of RUB at that time following its depreciation of more than 10% at the end of December 2024.
- Short-term fluctuations in value, especially RUB and USD, can have a significant impact on the net financial result. In the longer term, these effects are generally largely offset.

Financial results – margins

The highest Q1 EBITDA and EBIT Krka's history


€ million	Q1 2026	Q1 2025	change
Gross profit	342.0	304.4	12%
<i>Gross profit margin</i>	60.4%	58.3%	
EBITDA	175.7	157.4	12%
<i>EBITDA margin</i>	31.0%	30.1%	
EBIT	151.6	122.7	24%
<i>EBIT margin</i>	26.8%	23.5%	
Net profit	120.9	152.5	-21%
<i>Net profit margin</i>	21.4%	29.2%	




Performance Indicators

Maintaining long-term momentum


Revenue € million




EBITDA in € million



EPS in €



EBIT in € million




Dividend Policy and Share Buyback

Management committed to stable capital allocation

DPS and dividend yield* for the business year


Continually increasing dividend payout policy



Over €1,350m allocated for dividends in past 10y

Treasury shares

Repurchasing treasury shares whenever possible





Over €61m allocated for treasury shares in 2025

* Dividend yield calculated: dividend paid for the business year / price at the beginning of the year of pay date

Share Information and Shareholder Structure

Stable shareholder structure (KRKG SV)



- The price of Krka's share increased by 15% in Q1 2026 and stood at EUR 233 on March 31, 2026.
- **Krka proposed dividend for the year 2025 in amount of €9.1 per share**, which was 10.3% higher than the previous year. On an annual basis, this represents almost 4% dividend yield. **The total return on Krka's share in 2025 exceeded 50%.**
- Market capitalization: €8.0 billion as of 30 April 2026. Without treasury shares **market capitalization of €7.4 billion**. P/E: 18.5x and EV/EBITDA: 12.2x.
- Total number of shares: 32,793,448. Treasury shares: 2,510,983 (7.7%) as of 30 April 2026.
- The 10 largest shareholders own 13,713,974 shares (41.82% of all issued shares).

2025 Preliminary results and 2026 Guidance

Guidance in line with strategic goals

Guidance for 2026



SALES

€2,144m



NET INCOME

€405m




CAPEX


€140m

47% growth yoy

Sales (EUR million)



Net income (EUR million)



Revised Krka Group Development Strategy
for period **2026–2030**

Strategic orientation:

- Sales growth on average at least **5%** per ann.
- Average EBITDA margin of over **25%**

Krka Group Development Strategy 2026-2030

Amplifying our strategic foundation built on three strategic pillars


PROVIDING ACCESS TO MEDICINES



We supply

Providing uninterrupted and sufficient supply of high-quality, safe, effective, and innovative generic medicines at affordable prices

VERTICAL INTEGRATION



We leverage

Ensuring sufficient quantities of products, by leveraging the advantages of an efficient vertically integrated business model

VALUE CREATION



We create

Positive impacts of our operations reaching all stakeholders, and contribute to achieving strong business performance

Krka Group Development Strategy 2026-2030

Summary: key strategic objectives

To achieve 

≥ 5%	Average annual sales growth
-------------	-----------------------------

10%	Annual sales revenue allocated to R&D
------------	---------------------------------------

> 25%	Average EBITDA margin
-----------------	-----------------------

Top 5	Strengthen our position among the top 5 generic companies in all traditional markets
--------------	--

€150m	Average annual CAPEX allocated to expansion of manufacturing and R&D capacities
--------------	---


≥ 50%	Net profit of majority shareholders allocated to dividend payouts
--------------	---

Supported by

Effective in-house marketing and sales network
Competitive product offering – chronic diseases
Optimal product distribution and undisturbed supply
Organic growth and targeted acquisitions
Strengthening of Krka's brand reputation

 **PROVIDING ACCESS TO MEDICINES**

Development and production of API and FDF
Effective supply chain and sufficient FDF volume
High standards of quality assurance and control
Efficient regulatory procedures and product life-cycle
Strategic investments and partnerships, incl. JVs

 **VERTICAL INTEGRATION**

Long-term profitability
Long-term stable dividend policy
Employee potential development and management
Safe and healthy working environment
Sustainable business practices

 **VALUE CREATION**

ESG Governance of Krka Group

Creating long-term value for Krka's key stakeholders

Krka's strategic sustainability areas



1 ACCESSIBLE HEALTHCARE



2 PRODUCT QUALITY & PATIENT SAFETY



3 TALENT ATTRACTION & RETENTION



4 GOOD LEADERSHIP & GOVERNANCE PRACTICES



5 PLANET & CLIMATE CHANGE



6 COMPLIANCE, INTEGRITY & TRANSPARENCY

Key activities in 2025

- Second audited sustainability statement in accordance with ESRS standards.
- Update of the **strategy and ESG goals until 2030**.
- **Upgrade of sustainability reporting** in line with ESRS.
- For the third consecutive year, we achieved a **strong ESG rating**.




27 points above the pharmaceutical industry average.

20 points higher than most direct competitors.

Long-term Stable Growth

Growing faster than the global pharmaceutical market



H1 2026 estimated operating results release date: 9.7.2026; unaudited H1 2026 interim report: 23.7.2026

IR Contacts and Conferences in 2026

Maintaining high level of transparency

Krka Investors Relations Contact

KRKA IR Team

KRKA, d. d., Novo mesto
Šmarješka cesta 6
8501 Novo mesto
Europe, Slovenia

tel: + 386 7 33 17 591
e-mail: finance@krka.biz
www: www.krka.biz

Factsheet: [Krka](#)
Corporate facts: [Krka](#)
Video presentation: [Krka](#)



Public releases are published on the SEOnet information system of the Ljubljana Stock Exchange (www.ljse.si), ESPI information system of the Warsaw Stock Exchange (www.gpw.pl) and on the Krka's web page (<http://www.krka.biz/en/for-investors/financial-calendar/>). Silent periods are periods before the release dates of the reports. In silent periods Krka does not communicate information about its business performance. Silent periods end with the releases of the reports. Eventual changes of release dates will be published in the same manner as the financial calendar.

Investor Conferences in 2026

27 May 2026	The Finest CEElection Equity Conference 2026	ERSTE, Warsaw
2 – 3 June 2026	WOOD Frontier Investor Days	WOOD, London
9 June 2026	Ljubljana and Zagreb Stock Exchanges' Investor Days – CEE Investment Opportunities	ZSE, Zagreb
24 June 2026	AGCO – CEE Conference	AGCO, Warsaw
23 July 2026	KRKA: Webcast business performance results 1-6 2026	KRKA, online
8 Sep 2026	Webcast »Slovenian Listed Companies Online« (half year results)	LJSE, Online
13 Oct 2026	Financial Festival	LJSE, Novo mesto
13 Nov 2026	KRKA: Webcast business performance results 1-9 2026	KRKA, online
16 – 19 Nov 2026	Jefferies Global Healthcare Conference in London	Jefferies, London
26 Nov 2026	Ljubljana and Zagreb Stock Exchanges' Investor Days – CEE Investment Opportunities	LJSE, Ljubljana
2 – 5 Dec 2026	WOOD's Winter Wonderland EME Conference	WOOD, Prague

* Dates and times are provisional and are subject to change.

Disclaimer

The information, statements or data contained in this presentation has been prepared by Krka, tovarna zdravil, d. d., Novo mesto (hereinafter: the Company) and has been prepared solely for the purpose of informative presentation of the Company business operations. The presentation is not a summary or a compilation of all information relevant to any particular presentation issue. It is not purported to include every item, which may be of interest, nor does it purport to present full and complete disclosure with respect to the Company. The presentation should not be considered a comprehensive representation of the Company's performance.

The information and opinions contained in this presentation are provided as of the date of presentation and are subject to change, correction or completion without prior notice. None of the Company or any of its subsidiary or associated companies, or any of such legal entity's respective directors, officers, employees, or any other party undertakes, or is under any obligation to amend, correct or update this presentation or to provide any additional information that may arise in the future.

No reliance may be placed for any purposes whatsoever on the information contained in this document, or on its accuracy, promptness, correctness and completeness, or opinions contained in this document and no liability whatsoever is accepted for any such information or opinions or any use which may be made of them. The information contained in this document shall not constitute an invitation, an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any Company's shares securities in any jurisdiction. Except for the historical information contained, this presentation includes statements that are, or may be deemed to be, "forward-looking statements". These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Risks and uncertainties include but are not limited to Company's ability to successfully implement adopted strategy, growth and expansion plans, Company's ability to obtain/maintain regulatory approvals, implement technological changes, fluctuation in earnings, foreign exchange rates changes, Company's ability to manage international operations and exports, its exposure to market risks as well as other risks. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/ details. Investment decisions should be made only after full review of entirety of official publicly available documents and information, and investors/shareholders/public are advised to conduct their own investigation and analysis before taking any action with regard to their own specific objectives.

The company and any other information sources for this document bear no responsibility for any damages or losses resulting from the use of information provided in the presentation. The Company undertakes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein.



Living a healthy life.